Genome-wide association studies in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Genome-wide association studies (GWAS) have gained considerable momentum over the last couple of years for the identification of novel complex disease genes. In the field of Alzheimer's disease (AD), there are currently eight published and two provisionally reported GWAS, highlighting over two dozen novel potential susceptibility loci beyond the well-established APOE association. On the basis of the data available at the time of this writing, the most compelling novel GWAS signal has been observed in GAB2 (GRB2-associated binding protein 2), followed by less consistently replicated signals in galanin-like peptide (GALP), piggyBac transposable element derived 1 (PGBD1), tyrosine kinase, non-receptor 1 (TNK1). Furthermore, consistent replication has been recently announced for CLU (clusterin, also known as apolipoprotein J). Finally, there are at least three replicated loci in hitherto uncharacterized genomic intervals on chromosomes 14q32.13, 14q31.2 and 6q24.1 likely implicating the existence of novel AD genes in these regions. In this review, we will discuss the characteristics and potential relevance to pathogenesis of the outcomes of all currently available GWAS in AD. A particular emphasis will be laid on findings with independent data in favor of the original association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Genetic studies have identified numerous AD risk variants in immune‐ and microglial‐associated genes, highlighting the importance of microglia function in disease progression. 3 , 4 , 5 , 6 , 7”
From Alzheimer's disease–associated PLCG2 variants alter microglial state and function in human induced pluripotent stem cell–derived microglia‐like cells (2025) · cites this paper as [3]
In the citing paper
“In addition, we found the APOE and APP subnetwork within the vesicle mediated transport pathway which are among the most significant genetic risk factors for AD (Figure 5F).46,47,48”
From SCING: Inference of robust, interpretable gene regulatory networks from single cell and spatial transcriptomics (2023) · cites this paper as [46]
Citations
Cites
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“However, with the exception of one genetic variant, the 14-allele of the apolipoprotein E gene (APOE) (6,7) none of these candidates has been proven to consistently influence disease risk or onset age in more than a handful of samples.”
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891 · cited 1×
“For many genetically complex diseases, the GWAS approach has yielded an unexpectedly large number of genome-wide significant findings that were confirmed by independent follow-up studies (9,10).”
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 3×
“In the quest to uncover the late-onset AD genes, a vast body of data has been accrued over the past 30 years in well over 1200 studies assessing more than 500 different genes as potential risk factors, mostly using a candidate gene-based approach (5).”
InfluentialSelf-citationTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747
Self-citationCoon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
Assessment of cumulative evidence on genetic associations: interim guidelines
Ioannidis, J. P., Boffetta, P., Little, J., O'Brien, T. R., Uitterlinden, A. G., Vineis, P., Balding, D. J., Chokkalingam, A., Dolan, S. M., Flanders, W. D., et al. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dym159 · Cited by 552 · cited 2×
“Furthermore, this association is one of the few showing ‘strong’ epidemiologic credibility when applying interim grading criteria of the Human Genome Epidemiology Network (16).”
Research works printed but not linked: 3
- 2007, 54, 713
- 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 150, 50
- 2004, 43, 605
Cited by
Linking lipids to Alzheimer's disease: cholesterol and beyond
Di Paolo, G., & Kim, T.-W. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3012 · Cited by 972
The Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
Self-citationThe genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
Self-citationBioinorganic Chemistry of Alzheimer’s Disease
Kepp, K. P. (2012) · Chemical Reviews · doi:10.1021/cr300009x · Cited by 672
Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders
Brandebura, A. N., Paumier, A., Onur, T. S., & Allen, N. J. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00641-1 · Cited by 427
Pascual-Leone, A., Freitas, C., Oberman, L., Horvath, J. C., Halko, M., Eldaief, M., Bashir, S., Vernet, M., Shafi, M., Westover, B., et al. (2011) · Brain Topography · doi:10.1007/s10548-011-0196-8 · Cited by 388
“…genetic polymorphisms on distinct aspects of brain plasticity is the apolipoprotein E (APOE) susceptibility gene located on chromosome 19 and its e4 allele, which is thought to raise the risk of AD (e.g., Corder et al. 1993) in a dose-dependent manner (Bertram et al. 2007; Bertram and Tanzi 2009).”
BackgroundClusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
“Extensive genetic studies have identified genes that alter AD risk and numerous SNPs have also been identified associated with these genes (Bertram et al., 2007; Bertram and Tanzi, 2009; Harold et al., 2009; Lambert et al., 2009, 2013; Seshadri et al., 2010).”
BackgroundInflammasomes in neuroinflammation and changes in brain function: a focused review
Singhal, G., Jaehne, E. J., Corrigan, F., Toben, C., & Baune, B. T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00315 · Cited by 365
“Several factors such as genetic predisposition (Bertram and Tanzi, 2009; Kamboh et al., 2012), reduced synthesis of excitatory neurotransmitter acetyl choline (Babic, 1999), extracellular deposition of amyloid beta (Aβ) in the brain (Palop and Mucke, 2010), abnormalities in tau protein forming…”
BackgroundTargeting the correct HDAC(s) to treat cognitive disorders
Fischer, A., Sananbenesi, F., Mungenast, A., & Tsai, L.-H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.003 · Cited by 354
Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice?
Chen, Y., & Colonna, M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202717 · Cited by 339
“Genetic studies of human AD have demonstrated that many risk genes are expressed in microglia (Bertram and Tanzi, 2009; Cuyvers and Sleegers, 2016; Kunkle et al., 2019), suggesting that their response can impact disease onset and/ or progression.”
Background16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer’s Post-Mortem Brain
Emery, D. C., Shoemark, D. K., Batstone, T. E., Waterfall, C. M., Coghill, J. A., Cerajewska, T. L., Davies, M., West, N. X., & Allen, S. J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00195 · Cited by 317
“Further to this, multicenter genome-wide association studies (GWAS) have identified susceptibility loci on genes which may increase or decrease the risk of AD (Bertram and Tanzi, 2009).”
BackgroundYue, W.-H., Wang, H.-F., Sun, L.-D., Tang, F.-L., Liu, Z.-H., Zhang, H.-X., Li, W.-Q., Zhang, Y.-L., Zhang, Y., Ma, C.-C., et al. (2011) · Nature Genetics · doi:10.1038/ng.979 · Cited by 289
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases
Meredith, M. E., Salameh, T. S., & Banks, W. A. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9719-7 · Cited by 225
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208
“Some of these were identified using a candidate gene approach, others in the 11 LOAD GWAS (eg, CLU, CR1, PICALM, and GAB2) that have been performed to date.(9) The SORL1 gene, which directs -amyloidaway fromthe -amyloid–generatingpathway and was discovered using a candidate gene approach,(12) shows particularly impres…”
Genome-wide association study of CSF biomarkers Aβ 1-42 , t-tau, and p-tau 181p in the ADNI cohort
Kim, S., Swaminathan, S., Shen, L., Risacher, S. L., Nho, K., Foroud, T., Shaw, L. M., Trojanowski, J. Q., Potkin, S. G., Huentelman, M. J., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318204a397 · Cited by 206
Lee, S., Devanney, N. A., Golden, L. R., Smith, C. T., Schwartz, J. L., Walsh, A. E., Clarke, H. A., Goulding, D. S., Allenger, E. J., Morillo-Segovia, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112196 · Cited by 203
Watson, C. T., Roussos, P., Garg, P., Ho, D. J., Azam, N., Katsel, P. L., Haroutunian, V., & Sharp, A. J. (2016) · Genome Medicine · doi:10.1186/s13073-015-0258-8 · Cited by 201
A genome-wide scan for common variants affecting the rate of age-related cognitive decline
De Jager, P. L., Shulman, J. M., Chibnik, L. B., Keenan, B. T., Raj, T., Wilson, R. S., Yu, L., Leurgans, S. E., Tran, D., Aubin, C., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.033 · Cited by 197
“More details may be found in prior publications (Bienias et al., 2003; Evans et al., 2003).”
Aston, K. I., Krausz, C., Laface, I., Ruiz-Castane, E., & Carrell, D. T. (2010) · Human Reproduction · doi:10.1093/humrep/deq081 · Cited by 185
“Similar results have been obtained for other complex diseases including neurological disorders (Simon-Sanchez and Singleton, 2008; Bertram and Tanzi, 2009), autoimmune diseases (Lettre and Rioux, 2008; Graham et al., 2009), cardiovascular disease (Arking and Chakravarti, 2009) and a number of…”
ResultCurrent status on Alzheimer disease molecular genetics: from past, to present, to future
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq142 · Cited by 169
“Apart from the fact that all GWA studies except one [which was conducted in two extended pedigrees (37)] substantiated APOE 14 as the most significant finding, other genes were proposed as risk factors for late-onset AD [for an overview (38)].”
ResultAlzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 150
Parasuraman, R., & Jiang, Y. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.04.040 · Cited by 144
“GWAS research on neuropsychiatric diseases, such as autism (Weiss et al., 2008) and Alzheimer's disease (Bertram and Tanzi, 2009) has increased in recent years but studies of normal variation in cognition are still rare.”
Genetics of Alzheimer’s Disease
Vilatela, M. E. A., López, M., & Yescas, P. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.017 · Cited by 162
Duan, L., Bhattacharyya, B. J., Belmadani, A., Pan, L., Miller, R. J., & Kessler, J. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-3 · Cited by 159
Formation and function of apolipoprotein E-containing lipoproteins in the nervous system
Vance, J. E., & Hayashi, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.007 · Cited by 155
Hossini, A. M., Megges, M., Prigione, A., Lichtner, B., Toliat, M. R., Wruck, W., Schröter, F., Nuernberg, P., Kroll, H., Makrantonaki, E., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1262-5 · Cited by 136
“The AD-association with TNK1 which was also not expressed significantly in our experiments is unclear as several studies report ambiguous results [47,48].”
ResultThe role of histone acetylation in age-associated memory impairment and Alzheimer’s disease
Stilling, R. M., & Fischer, A. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.04.002 · Cited by 136
Sabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B., & Sperling, R. A. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr348 · Cited by 133
“…of Psychology and Center for Brain Science, Harvard University, Cambridge, MA 02128, USA, 4Howard Hughes Medical Institute, Cambridge, MA 02128, USA, 5Center for Human Genetic Research, Massachusetts General Hospital, Richard B. Simches Research Center, Boston, MA 02114, USA, 6Center for…”
BackgroundThe physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases
Park, S., Mathis, K. W., & Lee, I. K. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9275-3 · Cited by 137
“A HapMap based SNP genotyping approach showed that one SNP (rs11136000) in the CLU gene contributes to the pathogenesis of Alzheimer’s disease, which accounts for 2–3 % of total Alzheimer’s disease risk in the general population [21, 92].”
MethodBushman, D. M., Kaeser, G. E., Siddoway, B., Westra, J. W., Rivera, R. R., Rehen, S. K., Yung, Y. C., & Chun, J. (2015) · eLife · doi:10.7554/elife.05116 · Cited by 136
Interactome mapping suggests new mechanistic details underlying Alzheimer's disease
Soler-López, M., Zanzoni, A., Lluís, R., Stelzl, U., & Aloy, P. (2011) · Genome Research · doi:10.1101/gr.114280.110 · Cited by 124
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
Self-citationAlzheimer’s disease due to loss of function: A new synthesis of the available data
Kepp, K. P. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.06.004 · Cited by 124
“Genome-wide association studies (GWAS) have identified a range of other variations that may increase risk of AD[69][70], e.g. GAB2, GALP, TNK1, TREM2, PICALM, and CLU[54][70][71][72][73]. mechanistic hypotheses are shown in orange and key pathologies in red.”
BackgroundInfluentialSlow Excitotoxicity in Alzheimer's Disease
Ong, W.-Y., Tanaka, K., Dawe, G. S., Ittner, L. M., & Farooqui, A. A. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-121990 · Cited by 100
“-2 (PSEN-2) that cause early-onset familial AD, a huge effort has been put in identifying gene loci that are associated with increased risk for sporadic AD [7].”
Methionine-35 of A β (1–42): Importance for Oxidative Stress in Alzheimer Disease
Butterfield, D. A., & Sultana, R. (2011) · Journal of Amino Acids · doi:10.4061/2011/198430 · Cited by 124
“This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.”
MethodAlzheimer's disease genetics: current knowledge and future challenges
Hollingworth, P., Harold, D., Jones, L., Owen, M. J., & Williams, J. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2628 · Cited by 102
Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer’s Disease: Review and Meta-Analysis
Athanasaki, A., Melanis, K., Tsantzali, I., Stefanou, M., Ntymenou, S., Paraskevas, S. G., Κalamatianos, T., Boutati, E. I., Lambadiari, V., Voumvourakis, K. I., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10040778 · Cited by 120
Khanna, R., Wilson, S. M., Brittain, J. M., Weimer, J., Sultana, R., Butterfield, A., & Hensley, K. (2012) · Future Neurology · doi:10.2217/fnl.12.68 · Cited by 110
Herold, C., Hooli, B. V., Mullin, K., Liu, T., Roehr, J. T., Mattheisen, M., Parrado, A. R., Bertram, L., Lange, C., & Tanzi, R. E. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.218 · Cited by 111
“As seen in previous reports (reviewed elsewhere (23) none of our top 32 SNPs from Table 1 showed genomewide significance (with the exception of APOE SNPs) in the IGAP case-control GWAS dataset (24).”
ResultSelf-citationThat Obscure Object of Global Health
Fassin, D. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-007 · Cited by 111
Bekris, L. M., Lutz, F., & Yu, C.-E. (2012) · Journal of Human Genetics · doi:10.1038/jhg.2011.123 · Cited by 100
Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
“Finally, the GLPs recommend establishment of Quality Assurance procedures in the test facilities with the help of staff not directly involved in the conduct of studies to ensure that all the work is done as per prior commitment, with true representation of all the study data in the final reports and acknowledgement of…”
Alzheimer’s Disease: Pathogenesis and Therapeutic Interventions
Ogbodo, J. O., Agbo, C. P., Njoku, U. O., Ogugofor, M. O., Egba, S. I., Ihim, S. A., Echezona, A. C., Brendan, K. C., Upaganlawar, A. B., & Upasani, C. D. (2022) · Current Aging Science · doi:10.2174/1874609814666210302085232 · Cited by 78
Loe-Mie, Y., Lepagnol-Bestel, A.-M., Maussion, G., Doron-Faigenboim, A., Imbeaud, S., Delacroix, H., Aggerbeck, L., Pupko, T., Gorwood, P., Simonneau, M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq184 · Cited by 84
Genetics of age-related macular degeneration: current concepts, future directions
DeAngelis, M. M., Silveira, A. C., Carr, E. A., & Kim, I. K. (2011) · Seminars in Ophthalmology · doi:10.3109/08820538.2011.577129 · Cited by 94
Sultana, R., & Butterfield, D. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129018 · Cited by 83
“In addition, mutation in other genes, such as apolipoprotein E allele 4 (APOE 4), endothelial nitric oxide synthase-3, phosphatidylinositol-binding clathrin assembly protein (PICALM), clusterin (CLU, also called apolipoprotein J], and 2-macroglobulin, have been suggested as risk factors for AD [2–5].”
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020542 · Cited by 89
“The risk of AD is increased 4-fold by the presence of one copy [136].”
Functional Screening of Alzheimer Pathology Genome-wide Association Signals in Drosophila
Shulman, J. M., Chipendo, P. I., Chibnik, L. B., Aubin, C., Tran, D., Keenan, B. T., Kramer, P. L., Schneider, J. A., Bennett, D., Feany, M. Β., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.01.006 · Cited by 90
Ten Challenges of the Amyloid Hypothesis of Alzheimer’s Disease
Kepp, K. P. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160550 · Cited by 81
“Some notable ones are BIN1 , GAB2 , GALP , ABCA7 , TNK1 , TREM2 , PICALM , and CLU ; many of these are involved in membrane transport, endocytosis, immune system, and/or lipid metabolism [25, 34–37].”
Inhibition of acetylcholinesterase by green and white tea and their simulated intestinal metabolites
Okello, E. J., Leylabi, R., & McDougall, G. J. (2012) · Food & Function · doi:10.1039/c2fo10174b · Cited by 87
Tang, A. S., Rankin, K. P., Cerono, G., Miramontes, S., Mills, H., Roger, J., Zeng, B., Nelson, C., Soman, K., Woldemariam, S., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00573-8 · Cited by 86
“In particular, APOE is a well-established associated genetic locus 70 , and APOE polymorphism is known to modify AD risk, particularly in individuals carrying the ε4 allele 71 .”
Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 86
“31) alternate splicing variant is present in, but not specific to LOAD: The haplotype H1-specific expression of MAPT exon 10 [196] is active also in other tauopathies, and caused no signal in LOAD GWAS [197]; however, supported has been an epigenetic abnormal hypermethylation of MAPT in post-mortem LOAD neurons [198]…”
BackgroundInfluentialSchjeide, B.-M. M., Schnack, C., Lambert, J.-C., Lill, C. M., Kirchheiner, J., Tumani, H., Otto, M., Tanzi, R. E., Lehrach, H., Amouyel, P., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.196 · Cited by 82
“CSF-A 42 and total tau protein levels were determined using commercially available sandwich enzyme-linked immunosorbent assays Innotest -amyloid[1-42] and hTau Ag kits; Innogenetics, Gent, Belgium following the manufacturers instructions as previously described elsewhere.”
MethodSelf-citationA Brief History of Alzheimer's Disease Gene Discovery
Tanzi, R. E. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129044 · Cited by 71
“entire human genome for novel AD loci [46, 47] has”
Self-citationShen, L., Liao, L., Chen, C., Guo, Y., Song, D., Wang, Y., Chen, Y., Zhang, K., Ying, M., Li, S., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160913 · Cited by 74
Ma, S. L., Tang, N. L. S., Tam, C. W. C., Lui, V. W. C., Lam, L. C. W., Chiu, H. F. K., Driver, J. A., Pastorino, L., & Lu, K. P. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.018 · Cited by 74
A Microglial Signature Directing Human Aging and Neurodegeneration-Related Gene Networks
Mukherjee, S., Klaus, C., Pricop-Jeckstadt, M., Miller, J. A., & Struebing, F. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00002 · Cited by 68
Gadhave, K., Kumar, D., Uversky, V. N., & Giri, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21719 · Cited by 68
“GWAS identifies novel disease‐associated genetic variants by simultaneous testing of large number of genetic markers such as single nucleotide polymorphisms throughout the genome.(152,153) Recent GWAS studies identified AD‐associated genes”
BackgroundAxelrud, L. K., Santoro, M. L., Pine, D. S., Talarico, F., Gadelha, A., Manfro, G. G., Pan, P. M., Jackowski, A. P., Picon, F. A., Brietzke, E. M., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17050529 · Cited by 75
Genomics of Dementia:APOE- andCYP2D6-Related Pharmacogenetics
Cacabelos, R., Martínez, R., Fernández‐Novoa, L., Carril, J. C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., et al. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/518901 · Cited by 68
“1, probably implicating the existence of novel AD genes in these regions [91].”
BackgroundZetzsche, T., Rujescu, D., Hardy, J., & Hampel, H. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.48 · Cited by 60
Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease
Gonsalvez, I., Baror, R., Fried, P. J., Santarnecchi, E., & Pascual‐Leone, Á. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930113907 · Cited by 66
Investigation of 15 of the top candidate genes for late-onset Alzheimer’s disease
Belbin, O., Carrasquillo, M. M., Crump, M., Culley, O. J., Hunter, T. A., Ma, L., Bisceglio, G., Zou, F., Allen, M., Dickson, D. W., et al. (2011) · Human Genetics · doi:10.1007/s00439-010-0924-2 · Cited by 58
“Although, many variants have yet to be tested in follow-up studies, these six loci currently represent compelling GWAS signals worthy of follow-up investigation (Bertram and Tanzi 2009).”
BackgroundResultINPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease
Lin, P. B., Tsai, A. P., Soni, D., Lee‐Gosselin, A., Moutinho, M., Puntambekar, S. S., Landreth, G. E., Lamb, B. T., & Oblak, A. L. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12849 · Cited by 61
Schielzeth, H., Villamil, A. R., & Burri, R. (2018) · Molecular Ecology Resources · doi:10.1111/1755-0998.12780 · Cited by 61
“Several disease-related studies have found that QTL replicated, for example, for Alzheimer’s disease (Bertram & Tanzi, 2009) and for prostate cancer (with 63% replication success including across populations, Ishak & Giri, 2011).”
BackgroundXu, X., Warrington, A. E., Bieber, A. J., & Rodriguez, M. (2011) · CNS Drugs · doi:10.2165/11587830-000000000-00000 · Cited by 61
“The majority, lateonset Alzheimer disease (LOAD), is linked with multiple genes[46], some of which affect APP function[47–50].”
Alzheimer's loci: epigenetic associations and interaction with genetic factors
Chibnik, L. B., Yu, L., Eaton, M. L., Srivastava, G., Schneider, J. A., Kellis, M., Bennett, D. A., & De Jager, P. L. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.201 · Cited by 60
“Annals of Clinical and Translational Neurology 2015; 2(6): 636–647”
BackgroundThe Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230099 · Cited by 53
Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention?
Baune, B. T. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000140 · Cited by 47
“Several factors such as genetic predisposition [22,23], reduced synthesis of excitatory neurotransmitter acetylcholine [24], extracellular deposition of amyloid b in the brain [25], abnormalities in tau protein forming neurofibrillary tangles leading to disintegration of microtubules [26] and oxidative stress and infl…”
BackgroundJohnson, L. A., Torres, E. R., Weber Boutros, S., Patel, E., Akinyeke, T., Alkayed, N. J., & Raber, J. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17746186 · Cited by 56
“Individuals with T2D show lower resting blood flow in the brain and a reduced ability to maintain stable and sufficient cerebral blood flow (CBF) compared to controls.21,22 The microvasculature within peripheral tissues is particularly sensitive to insulin, and this sensitivity is impaired by obesity and IR.23 Insulin…”
BackgroundInfluentialAlzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development
Savonenko, A. V., Melnikova, T., Hiatt, A., Li, T., Worley, P. F., Troncoso, J. C., Wong, P. C., & Price, D. L. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.211 · Cited by 57
“More recently, the presence of alleles of other genes such as ApoE has been shown to be significant risk factors for late-onset disease (Bertram and Tanzi, 2009; Kim et al, 2011).”
BackgroundSeo, J., Lee, K.-W., Kim, T., Baek, I., Im, J., & Han, P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.02.035 · Cited by 55
Effects of ApoE4 and maternal history of dementia on hippocampal atrophy
Andrawis, J. P., Hwang, K. S., Green, A. E., Kotlerman, J., Elashoff, D., Morra, J. H., Cummings, J. L., Toga, A. W., Thompson, P. M., & Apostolova, L. G. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.020 · Cited by 54
Genetic Mouse Models of Neurodegenerative Diseases
Trancikova, A. K., Ramonet, D., & Moore, D. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00012-1 · Cited by 54
ACAT inhibition and amyloid beta reduction
Bhattacharyya, R., & Kovacs, D. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.04.003 · Cited by 53
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease
Zhang, T., Kim, B. M., & Lee, T. H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-023-00395-5 · Cited by 53
Intermediate Phenotypes Identify Divergent Pathways to Alzheimer's Disease
Shulman, J. M., Chibnik, L. B., Aubin, C., Schneider, J. A., Bennett, D. A., & De Jager, P. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011244 · Cited by 44
“Genome-wide association (GWA) studies have emerged as a promising approach to identify susceptibility loci in common diseases with complex genetic inheritance, but until recently, most GWA scans in AD have been relatively underpowered, and identified loci have not been consistently replicated [5–14].”
BackgroundCacabelos, R., Fernández‐Novoa, L., Martínez‐Bouza, R., McKay, A., Carril, J. C., Lombardi, V., Corzo, L., Carrera, I., Tellado, I., Nebril, L., et al. (2010) · Pharmaceuticals · doi:10.3390/ph3103040 · Cited by 51
“1, probably implicating the existence of novel AD genes in these regions [86].”
BackgroundEffect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex
Suri, S., Emir, U. E., Stagg, C. J., Near, J., Ralf Mekle, A., Schubert, F., Zsoldos, E., Mahmood, A., Singh‐Manoux, A., Mika Kivimaki, B., et al. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.031 · Cited by 50
“The APOE ε4 allele is the best-established genetic risk factor for sporadic lateonset AD (Bertram and Tanzi, 2009), whereas the rarer (and relatively understudied) ε2 allele is believed to be protective against AD (Suri et al.”
BackgroundAfsar, A., Castro, M. D. C. C., Soladogun, A. S., & Li, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087258 · Cited by 49
Alichniewicz, K., Brunner, F., Klünemann, H. H., & Greenlee, M. W. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.010 · Cited by 49
Iron Regulates Apolipoprotein E Expression and Secretion in Neurons and Astrocytes
Xu, H. J., Perreau, V. M., Dent, K. A., Bush, A. I., Finkelstein, D. I., & Adlard, P. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150797 · Cited by 47
Links between copper and cholesterol in Alzheimer's disease
Hung, Y. H., Bush, A. I., & Fontaine, S. L. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00111 · Cited by 46
“Of these other apolipoproteins, ApoJ has gained increasing research interest in recent years with its emergence as another key genetic risk factor for AD from genome-wide association studies (Bertram and Tanzi, 2009; Harold et al., 2009).”
BackgroundJi, H., Dai, D., Wang, Y., Jiang, D., Zhou, X., LIN, P., JI, X., LI, J., Zhang, Y., Yin, H., et al. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2327 · Cited by 45
Morihara, T., Hayashi, N., Yokokoji, M., Akatsu, H., Silverman, M. A., Kimura, N., Sato, M., Saito, Y., Suzuki, T., Yanagida, K., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307345111 · Cited by 41
“AD is a complex disease not only genetically but also, neuropathologically and symptomatically (11), with its clinical diagnosis often ambiguous.”
BackgroundAlzheimer’s Disease: Genetic Polymorphisms and Rate of Decline
Schmidt, C., Wolff, M., von Ahsen, N., & Zerr, I. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000336790 · Cited by 38
Medical Anthropology and Mental Health: Five Questions for the Next Fifty Years
Kleinman, A. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-008 · Cited by 43
The APP intracellular domain (AICD) potentiates ER stress-induced apoptosis
Kögel, D., Concannon, C. G., Müller, T., König, H., Bonner, C., Poeschel, S., Chang, S., Egensperger, R., & Prehn, J. H. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.012 · Cited by 42
“The functional consequences of this variant are not clear at present, but it was proposed that it might lead to alternative splicing or expressional regulation of ApoJ/clusterin mRNA (Bertram and Tanzi, 2009).”
BackgroundRassoul, R. A., Alves, S., Pantesco, V., Vos, J. D., Michel, B. F., Perret, M., Mestre‐Francés, N., Verdier, J., & Devau, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012770 · Cited by 42
“Finally, the expression of CLU ( APOJ , Clusterin ), which is considered as a risk factor for AD [39,40] was significantly increased in both ‘‘AD-like’’ animals.”
Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene
Lancaster, T. M., Baird, A. L., Wolf, C., Jackson, M. C., Johnston, S. J., Donev, R., Thome, J., & Linden, D. E. J. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.02.001 · Cited by 41
“Recent GWAS (Genome Wide Association Studies) have identified and replicated a risk locus (rs11136000) on the CLU (APOJ) gene (Bertram and Tanzi, 2009; Carrasquillo et al., 2010; ts reserved.”
Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2011) · Wiley eBooks · doi:10.1002/9781444341256.ch9 · Cited by 41
Self-citationDementia Entanglements in a Postgenomic Era
Lock, M. M. (2010) · Science Technology & Human Values · doi:10.1177/0162243910388022 · Cited by 40
Lancaster, T. M., Brindley, L. M., Tansey, K. E., Sims, R. C., Mantripragada, K., Owen, M. J., Williams, J., & Linden, D. E. J. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.012 · Cited by 36
Arab, L., Sadeghi, R., Walker, D. G., Lue, L.-F., & Sabbagh, M. N. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376334 · Cited by 37
“Possession of a single or two copies of the apoE4 allele is the most significant risk factor for developing sporadic AD [76, 77].”
BackgroundImaging Epigenetics in Alzheimer’s Disease
Lista, S., Garaci, F., Toschi, N., & Hampel, H. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990370 · Cited by 36
“These cases, in which the genetic background is uncertain, are referred to as sporadic AD (sAD) [20,24].”
BackgroundReceptor Recycling by Retromer
Carosi, J. M., Denton, D., Kumar, S., & Sargeant, T. J. (2023) · Molecular and Cellular Biology · doi:10.1080/10985549.2023.2222053 · Cited by 36
“linked with Alzheimer’s disease, however, these “hits” failed to reach genome-wide significance in larger and more robust studies.(66,176) Amyotrophic lateral sclerosis.”
BackgroundMaking Peasants Protestant and Other Projects: Medical Anthropology and Its Global Condition
Cohen, L. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-005 · Cited by 36
Littman, R., Cheng, M., Wang, N., Peng, C., & Yang, X. (2023) · iScience · doi:10.1016/j.isci.2023.107124 · Cited by 35
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Max Planck Institute for Molecular Genetics (DE)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10-06
- Volume
- 18
- Issue
- R2
- Pages
- R137-R145
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC2758713
- OpenAlex
- W2164868723
- Cited by
- 257
- References
- 40
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 15 · 2023: 14 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 6 · 2018: 16 · 2017: 10 · 2016: 12 · 2015: 9 · 2014: 11 · 2013: 16 · 2012: 32
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genome-wide association study, genetic susceptibility loci, apolipoprotein E, Gab2, Galp, TNK1, clusterin, pathogenesis
- MeSH terms
- Alzheimer Disease, Humans, Genome, Human, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.